Advertisement

Allele Specific PCR: A Cost Effective Screening Method for MPL Mutations in Myeloproliferative Neoplasms

  • Arun Kumar Arunachalam
  • Hemamalini Suresh
  • Vikram Mathews
  • Poonkuzhali Balasubramanian
Correspondence

Dear editor,

Philadelphia negative myeloproliferative neoplasm primarily includes Polycythemia Vera, Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) [1]. Majority of the ET and PMF patients have mutations in JAK2 (JAK2 V617F) or CALR genes. Mutations mapping to the juxtamembrane region of the thrombopoietin receptor MPL (exon 10) have been described in 5–10% of PMF patients and 1% of ET patients, who were negative for JAK2 and CALR mutations [2]. These MPL mutations are gain of function mutations leading to receptor activation in the absence of thrombopoietin binding with constitutive activation of the JAK-STAT signaling. Spontaneous activation of this receptor leads to uncontrolled overactivity resulting in myeloproliferative neoplasms [3].

The MPLgene located on chromosome 1p34 has 12 exons coding for the thrombopoietin receptor. Four recurrent [c.1544G > T (W515L), c.1543_1544TG > AA (W515 K), c.1543_1544TG > GC (W515A) and c.1514G > A (S505 N)] and two rare...

Notes

Compliance with Ethical Standards

Conflict of interest

The authors have no competing interest.

Ethical Approval

This is a retrospective analysis using DNA extracted from EDTA blood sample that has been collected for routine molecular diagnostic procedures (JAK2, CALR) in patients with myeloproliferative neoplasms in our institution. No additional sample was collected from any patient for this study. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Supplementary material

12288_2018_982_MOESM1_ESM.jpg (82 kb)
Supplementary material 1 (JPEG 81 kb)
12288_2018_982_MOESM2_ESM.docx (14 kb)
Supplementary material 2 (DOCX 13 kb)

References

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMedGoogle Scholar
  2. 2.
    Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10):3472–3476CrossRefPubMedGoogle Scholar
  3. 3.
    Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7):e270CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Boyd EM, Bench AJ, Fernandez AG, Anand S, Vaghela KJ, Beer P et al (2010) Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 149(2):250–257CrossRefPubMedGoogle Scholar
  5. 5.
    Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL (2013) Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn 15(6):810–818CrossRefPubMedGoogle Scholar
  6. 6.
    Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kroger N (2010) Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 45(9):1404–1407CrossRefPubMedGoogle Scholar
  7. 7.
    Hussein K, Bock O, Theophile K, Schulz Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H (2009) MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 23(5):852–855CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Arun Kumar Arunachalam
    • 1
  • Hemamalini Suresh
    • 1
  • Vikram Mathews
    • 1
  • Poonkuzhali Balasubramanian
    • 1
  1. 1.Department of HaematologyChristian Medical College and HospitalVelloreIndia

Personalised recommendations